| Name | Alogliptin Benzoate |
| Description | Alogliptin Benzoate (SYR 322)(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammatory responses by preventing the toll-like receptor 4 (TLR-4)-mediated formation of proinflammatory cytokines. |
| In vitro | Alogliptin(SYR-322) is a potent inhibitor of DPP-4 and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9. Alogliptin is not an inhibitor of CYP-450 enzymes and does not block the hERG channel at concentrations up to 30 μM. [1] |
| In vivo | Alogliptin(SYR-322) produces dose-dependent improvements in glucose tolerance and increases plasma insulin levels in female Wistar fatty rats. [1] Acute administration of alogliptin results in a significant decrease in plasma DPP-4 activity, and increases plasma active GLP-1. Alogliptin improves glucose tolerance at a dose of 0.3 mg/kg and higher, with a dose-dependent increase in plasma IRI, suggesting that improved glucose tolerance results from the ability of alogliptin to enhance insulin secretion. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.17 mM), Sonication is recommended.
DMSO : 55 mg/mL (119.17 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 2 mg/mL (4.33 mM), Sonication is recommended.
|
| Keywords | SYR-322 | SYR322 | Inhibitor | inhibit | Ferroptosis | DPP-4 | DPP4 | DPP | Dipeptidyl Peptidase | diabetes | Alogliptin Benzoate | Alogliptin |
| Inhibitors Related | Rosiglitazone | L-Glutamic acid | Sorafenib | Curcumin | Gallic Acid Monohydrate | Artemisinin | L-Cystine | L-Glutamine | L-Glutamic acid monosodium salt | Alloxan monohydrate | 4'-Hydroxychalcone | Cisplatin |
| Related Compound Libraries | Highly Selective Inhibitor Library | Ferroptosis Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
